Thank you to AACR, American Cancer Society, and Cancer Research Communications for supporting our work from the Blossom Damania 🔬🧬🧪🦠🧫 at UNC Lineberger ! I had a great time at #AACR24 and meeting all the wonderful people involved in these organizations ACS Research ACSNews #lymphoma #CancerResearch

Wonderful to see our #liquidbiopsies research highlighted in the #AACR24 #precisiononcology special series! Read the open access Clinical Cancer Research study: aacrjournals.org/clincancerres/… AACR Johns Hopkins Thoracic Oncology Johns Hopkins Medicine Lavanya Sivapalan Joseph Murray

If you enjoyed the session on the Tumor Microbiome at #AACR24, be sure to read this recent Convergence Science paper on the relationship between stress and bacteria in #coloncancer. bit.ly/4awkWqs

Such a delight to meet with the terrific Arul Chinnayan at AACR - Vivek Subbiah, MD #AACR24 #AACR #Cancer #CancerResearch #OncoDaily #Oncology #SarahCannonResearchInstitute oncodaily.com/46291.html

The closing plenary is over, and so is #AACR24. We thank Program Chairs Keith T. Flaherty and Christina Curtis and the entire Program Committee for developing an inspiring meeting, and we look forward to seeing everyone in Chicago for #AACR25.

Even though #AACR24 has come to an end, you can continue the celebration by viewing the Cancer Discovery April issue full of special commentaries including this one by our fearless Editors-in-Chief Cantley Lab and Luis Diaz doi.org/10.1158/2159-8…

A Vision for Democratizing Next-Generation Oncology Clinical Trials [Apr 4, 2024] Vivek Subbiah, MD Horgan Ishwaria Subbiah, MD MS FASCO Cancer Discovery aacrjournals.org/cancerdiscover… #PrecisionMedicine #ClinicalTrials #ctsm

Thanks to 23K participants & AACR colleagues for a great #AACR24. It was a diverse, multidimensional, concentrated extract of global cancer research. Next step: turning presentations to publications! Happy to help with that at Blood Cancer Discovery.

From San Diego #AACR2024 to the Colosseum in Rome. I had the best time presenting our Cancer Discovery research Istituto Superiore di Sanità. Engaged in insightful discussions about DNA repair and genome stability with Pietro Pichierri 🇮🇹🇪🇺 @[email protected] and Annapaola Franchitto! #GenomeStability #DNARepair

In Cancer Prevention Research from Johns Hopkins Kimmel Cancer Center & MD Anderson Cancer Center #PancreaticCancer teams: Germline Testing identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors aacrjournals.org/cancerpreventi… In an unselected population, 1 in 5 harbor germline alterations

And senCAFs are differ in the pancreas! Yup, tissues ARE different. @CD_AARC wotj David DeNardo WUSM aacrjournals.org/cancerdiscover…

Check it out-the world of CAFs is more complex-senescent CAFs (senCAFs) drive breast cancer progression by inhibiting NK cells @CD_ AACR. aacrjournals.org/cancerdiscover…

Congratulations to Bell and Yi on back to back Cancer Discovery papers. Go Sheila Stewart and Siteman Cancer Center aacrjournals.org/cancerdiscover…

Turns our MyCAFs become Senescent (SenCAFs) and can drive both breast and pancreas cancer progression through immune modulation. See just now online at Cancer Discovery aacrjournals.org/cancerdiscover… aacrjournals.org/cancerdiscover…

Now online in Cancer Discovery: back-to-back papers from the labs of Sheila Stewart and David DeNardo WUSM on immunosuppression by senescent CAFs in breast and pancreatic cancers doi.org/10.1158/2159-8… doi.org/10.1158/2159-8… Jennifer Jiayu Ye Jad Belle #DevashishSen Test Account Siteman Cancer Center

I spend a lot of time outside—walking my dog, hiking—you name it. Wearing sunscreen or protective clothing is a regular part of my routine. Protecting your skin from UV radiation isn't just for #MelanomaMonday, it's an everyday essential! ☀️ go.nih.gov/MHufnZd #SkinCancer

Read the paper featured on this month's cover: #Sotorasib Is a pan-RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C cancers, by Doug Rubinson, Noritaka Tanaka, Andrew Aguirre, Ryan Corcoran et al. bit.ly/3UKYTXw Dana-Farber Mass General Cancer Center #KRAS

Well it’s official…my time at Cancer Discovery has come to end and I start a new chapter as an Oncology Scientist/Medical Writer at National Comprehensive Cancer Network (NCCN). It was such a pleasure to work to promote high impact cancer research but I am excited to shift and work on the clinical oncology guidelines!

Updated National Comprehensive Cancer Network (NCCN) guidelines (1.2025) are in, with some major changes for systemic therapies: 1) Ipi+Nivo is now a preferred regimen in fav-risk ccRCC 2) Len+Pem/Cabo+Nivo are now preferred regimens for non-clear cell RCC 3) Adjuvant Pembro is now Category 1 KidneyCAN

Have been sitting on this for a few days and am now really excited to share *4* papers just published online today in Cancer Discovery, with variations on the theme of cancer cell #plasticity as a mechanism of resistance to #KRAS inhibition aacrjournals.org/cancerdiscover… (🧵)